Form 4: Jazz Pharma Director's RSU Grant & Tax-Related Share Sale

Jazz Pharmaceuticals plc director Jennifer E. Cook received a grant of 3,507 restricted stock units and sold 1,805 shares to cover tax obligations from a prior RSU vesting.

Summary

• Jennifer E. Cook, a Director of Jazz Pharmaceuticals plc, was granted 3,507 restricted stock units (RSUs) on August 7, 2025.
• These newly granted RSUs represent a contingent right to receive one ordinary share per unit and are scheduled to vest in full on July 24, 2026, subject to continuous service and other conditions.
• On August 8, 2025, Ms. Cook disposed of 1,805 ordinary shares at a price of $111.2494 per share.
• This disposition was made to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
• Following these transactions, Ms. Cook directly beneficially owns 10,837 ordinary shares.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions involving an RSU grant and a tax-related share sale, which are standard compensation and tax management activities for corporate directors and do not indicate significant positive or negative sentiment regarding the company's performance or outlook.

Positives

• The grant of 3,507 restricted stock units to a director aligns director incentives with shareholder value.

Negatives

• The sale of 1,805 shares, although for tax purposes, reduces the director's direct ownership.

Future Outlook

The 3,507 restricted stock units granted on August 7, 2025, are expected to vest in full on July 24, 2026, subject to continuous service and certain additional conditions.

Industry Context

This is a routine insider transaction for a pharmaceutical company, reflecting standard compensation practices for directors. It does not provide broader industry trends.

Stakeholder Impact

• Shareholders: Minor dilution from RSU grant (future vesting), but also aligns director's interests. The tax-related sale is a routine event.
• Director (Jennifer E. Cook): Receives future equity compensation and manages tax liabilities from prior compensation.

Next Steps

• The 3,507 restricted stock units granted on August 7, 2025, are expected to vest in full on July 24, 2026, subject to continuous service and other conditions.

Key Dates

Keywords

Jazz Pharmaceuticals, JAZZ, Jennifer Cook, Director, SEC Form 4, Restricted Stock Units, RSU, Share Grant, Share Sale, Insider Transaction, Beneficial Ownership, Tax Obligations